Advertisement

Topics

MSD's Keytruda with Pfizer's Inlyta beats Sutent in most common #kidneycancer http://bit.ly/2pXKaJH  #pharma

07:06 EDT 19 Oct 2018 | Pharmafile

MSD's Keytruda with Pfizer's Inlyta beats Sutent in most common http://bit.ly/2pXKaJH 

Original Article: MSD's Keytruda with Pfizer's Inlyta beats Sutent in most common #kidneycancer http://bit.ly/2pXKaJH  #pharma

NEXT ARTICLE

More From BioPortfolio on "MSD's Keytruda with Pfizer's Inlyta beats Sutent in most common #kidneycancer http://bit.ly/2pXKaJH  #pharma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...